Hankuk Carbon Co., Ltd. (017960.KS)
Miryang-si, KR
Operating out of South Korea, Hankuk Carbon Co., Ltd. is a leading manufacturer and supplier of advanced composite materials. The company's diverse product portfolio includes carbon prepregs, utilized in both aerospace and various industrial sectors, alongside carbon fiber sheets designed for structural repair in buildings and bridges. Furthermore, they supply essential LNG heat insulation panels for effective storage and transportation. Their offerings extend to glass papers, which find applications in a wide range of products such as floor decoration materials, tile carpets, print substrates, waterproof road surfaces, thermal insulation panels, and filtration systems. Additionally, Hankuk Carbon manufactures components for the automotive and railway industries, interior and exterior sandwich panels, and specialized heat insulating panels for maritime vessels. They also produce various laminates, catering to archery equipment, electrical insulation needs, and structural reinforcement in construction. Their product line further encompasses copper-clad laminates for Printed Circuit Board (PCB) substrates, dry films, and components for both household goods and semiconductor packaging. Established in 1984, Hankuk Carbon Co., Ltd. maintains its headquarters in Miryang, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.03% | -20.17% | -29.37% | +0.14% | +30.50% | +32.61% | +76.08% | +237.61% | +213.19% | +483.20% | +475.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+22.5% ★ Q1'26: -5.7% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+374.9% ★ Q1'26: -30.6% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+8.0% Q1'26: +5.1% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+14.4% ★ Q1'26: +19.4% (vs Q1'25)
-
ROIC Chemicals: +3.4%+22.6% ★ Q1'26: +26.5% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+5.5% Q1'26: +2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.72× ★ Q1'26: 0.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
242.54B
est: 251.00B (-3.4%)
|
257.63B
est: 257.60B (+0.0%)
|
239.06B
est: 242.50B (-1.4%)
|
226.70B
est: 223.85B (+1.3%)
|
273.40B
est: 273.20B (+0.1%)
|
411.67B
est: 411.50B (+0.0%)
|
367.83B
est: 367.83B (+0.0%)
|
369.27B
est: 365.66B (+1.0%)
|
594.42B
est: 575.64B (+3.3%)
|
741.74B
est: 745.11B (-0.5%)
|
908.81B
est: 908.85B (0.0%)
|
963.66B
958.75B – 968.56B
+6.0% YoY
|
999.59B
861.88B – 1.08T
+3.7% YoY
|
1.12T
1.03T – 1.16T
+11.7% YoY
|
| EBITDA |
32.27B
est: 27.00B (+19.5%)
|
31.10B
est: 27.71B (+12.2%)
|
17.16B
est: 26.09B (-34.2%)
|
12.13B
est: 24.08B (-49.6%)
|
32.81B
est: 29.39B (+11.6%)
|
85.26B
est: 44.27B (+92.6%)
|
41.16B
est: 39.57B (+4.0%)
|
42.90B
est: 39.34B (+9.0%)
|
14.72B
est: 61.93B (-76.2%)
|
57.86B
est: 75.76B (-23.6%)
|
161.34B
est: 92.41B (+74.6%)
|
97.98B
97.48B – 98.48B
+6.0% YoY
|
101.63B
87.63B – 109.38B
+3.7% YoY
|
113.48B
105.23B – 118.17B
+11.7% YoY
|
| EBIT |
30.65B
est: 19.74B (+55.2%)
|
24.83B
est: 20.26B (+22.5%)
|
10.81B
est: 19.08B (-43.4%)
|
6.15B
est: 17.61B (-65.1%)
|
26.45B
est: 21.49B (+23.1%)
|
76.86B
est: 32.37B (+137.4%)
|
31.19B
est: 28.93B (+7.8%)
|
29.83B
est: 28.76B (+3.7%)
|
-2.54B
est: 45.28B (-105.6%)
|
33.50B
est: 52.24B (-35.9%)
|
130.95B
est: 63.71B (+105.5%)
|
67.56B
67.21B – 67.90B
+6.0% YoY
|
70.08B
60.42B – 75.42B
+3.7% YoY
|
78.24B
72.56B – 81.48B
+11.7% YoY
|
| Net Income |
22.69B
est: 24.12B (-5.9%)
|
16.47B
est: 19.83B (-17.0%)
|
744.13M
est: 13.76B (-94.6%)
|
5.63B
est: -24.61M (+22,963.9%)
|
17.70B
est: 20.37B (-13.1%)
|
57.38B
est: 53.16B (+7.9%)
|
14.35B
est: 16.02B (-10.4%)
|
20.26B
est: 19.18B (+5.6%)
|
-13.45B
est: -1.31B (-927.6%)
|
20.32B
est: 25.40B (-20.0%)
|
101.66B
est: 100.81B (+0.8%)
|
128.62B
128.46B – 128.79B
+27.6% YoY
|
145.28B
136.65B – 154.18B
+12.9% YoY
|
158.03B
143.10B – 166.52B
+8.8% YoY
|
| SGA |
7.60B
est: 9.45B (-19.5%)
|
9.37B
est: 9.69B (-3.3%)
|
9.58B
est: 9.13B (+5.0%)
|
7.91B
est: 8.42B (-6.1%)
|
10.79B
est: 10.28B (+5.0%)
|
14.83B
est: 15.49B (-4.2%)
|
11.85B
est: 13.84B (-14.4%)
|
13.16B
est: 13.76B (-4.4%)
|
22.39B
est: 21.66B (+3.4%)
|
34.58B
est: 28.70B (+20.5%)
|
36.79B
est: 35.01B (+5.1%)
|
37.12B
36.93B – 37.31B
+6.0% YoY
|
38.51B
33.20B – 41.44B
+3.7% YoY
|
43.00B
39.87B – 44.77B
+11.7% YoY
|
| EPS |
578.00
est: 490.00 (+18.0%)
|
402.00
est: 403.00 (-0.2%)
|
18.00
est: 279.50 (-93.6%)
|
137.89
est: -0.50 (+27,678.0%)
|
431.52
est: 413.87 (+4.3%)
|
1,377.10
est: 1,080.00 (+27.5%)
|
333.52
est: 325.42 (+2.5%)
|
470.94
est: 389.67 (+20.9%)
|
-305.00
est: -26.59 (-1,047.0%)
|
412.42
est: 489.35 (-15.7%)
|
1,958.50
est: 1,942.14 (+0.8%)
|
2,477.94
2,474.73 – 2,481.15
+27.6% YoY
|
2,798.73
2,632.46 – 2,970.35
+12.9% YoY
|
3,044.35
2,756.77 – 3,207.92
+8.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Samsung KODEX Momentum PLUS ETF 244620.KS | 2.26% | 239.3K | 0.30% |
| 2 | Kodex Energy&Chemicals 117460.KS | 1.59% | 268.7K | 0.45% |
| 3 | Kodex 200 Mid-Small 226980.KS | 0.82% | 112.1K | 0.30% |
| 4 | Kodex MSCI Momentum 275280.KS | 0.13% | 31.9K | 0.30% |
| 5 | First Trust Developed Markets ex-US Small Cap AlphaDEX Fund FDTS | 0.10% | 13.3K | 0.80% |
| 6 | Kodex MSCI Quality 275300.KS | 0.09% | 33.3K | 0.30% |
| 7 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.07% | 81.4K | 0.42% |
| 8 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.05% | 36.6K | 0.74% |
| 9 | Kodex 200TR 278530.KS | 0.04% | 2.44M | 0.05% |
| 10 | Samsung KODEX 200 ETF 069500.KS | 0.04% | 7.82M | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Myung-Hwa Lee | Co-CEO & Director | 1B | female |
| Moon-Soo Cho | Co-CEO & Director | 1B | male |
| In-Kyu Lee | Head of LNG/IP Department | — | — |
| InHo Sim | MD & Head of Finance Division | — | — |
| Jong-Hwa Ha | Head of Employment Department | — | — |
| Myung-Rea Cho | Head of Carbon Fiber Department | — | — |
| SeungGyu Lim | MD & Head of Material Business Division | — | — |
| EunSeon Lee | MD & Defense Parts Development Manager | — | — |
| TaeHo Noh | MD & Head of Defense Business Division | — | — |
| HeeSoon Kang | MD & Strategic Planning Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 017960.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
